Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $662,550 - $824,500
5,000 Added 25.0%
25,000 $3.37 Million
Q1 2023

May 12, 2023

BUY
$144.61 - $166.54 $2.89 Million - $3.33 Million
20,000 New
20,000 $3.19 Million
Q3 2022

Nov 02, 2022

BUY
$134.21 - $153.93 $402,630 - $461,790
3,000 Added 100.0%
6,000 $805,000
Q2 2022

Aug 02, 2022

SELL
$137.62 - $174.96 $963,340 - $1.22 Million
-7,000 Reduced 70.0%
3,000 $459,000
Q1 2022

May 11, 2022

SELL
$131.98 - $163.75 $9.24 Million - $11.5 Million
-70,000 Reduced 87.5%
10,000 $1.62 Million
Q4 2021

Jan 18, 2022

BUY
$107.43 - $135.93 $8.54 Million - $10.8 Million
79,500 Added 15900.0%
80,000 $10.8 Million
Q3 2021

Oct 20, 2021

SELL
$106.4 - $120.78 $28,089 - $31,885
-264 Reduced 34.55%
500 $5.39 Million
Q2 2021

Jul 19, 2021

BUY
$105.21 - $117.21 $35,140 - $39,148
334 Added 77.67%
764 $8.61 Million
Q1 2021

Apr 14, 2021

SELL
$102.3 - $112.62 $48,081 - $52,931
-470 Reduced 52.22%
430 $4.65 Million
Q4 2020

Feb 25, 2021

BUY
$80.49 - $108.67 $32,195 - $43,468
400 Added 80.0%
900 $96,000
Q3 2020

Oct 19, 2020

SELL
$85.91 - $100.83 $2,147 - $2,520
-25 Reduced 4.76%
500 $4.38 Million
Q2 2020

Aug 06, 2020

BUY
$73.37 - $98.18 $15,774 - $21,108
215 Added 69.35%
525 $5.15 Million
Q1 2020

Apr 28, 2020

SELL
$64.5 - $97.79 $128,355 - $194,602
-1,990 Reduced 86.52%
310 $2.36 Million
Q4 2019

Jan 13, 2020

BUY
$72.13 - $90.25 $163,590 - $204,687
2,268 Added 7087.5%
2,300 $20.4 Million
Q4 2018

Jan 23, 2019

BUY
$77.85 - $96.01 $2,491 - $3,072
32 New
32 $295,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $355B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Clear Street Markets LLC Portfolio

Follow Clear Street Markets LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clear Street Markets LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clear Street Markets LLC with notifications on news.